These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10195609)

  • 1. Efficacy of Vi polysaccharide vaccine against Salmonella typhi.
    Arya SC
    Vaccine; 1999 Mar; 17(9-10):1015-6. PubMed ID: 10195609
    [No Abstract]   [Full Text] [Related]  

  • 2. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
    Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vi Capsular Polysaccharide Produced by Recombinant
    Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
    Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply.
    Keddy KH; Klugman KP; Robbins JB
    Vaccine; 1998; 16(9-10):871-2. PubMed ID: 9682329
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of Salmonella typhi Vi capsular polysaccharide vaccine in South Africa.
    Arya SC
    Vaccine; 1997 Feb; 15(2):244. PubMed ID: 9066045
    [No Abstract]   [Full Text] [Related]  

  • 6. Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever.
    Giannelli C; Cappelletti E; Di Benedetto R; Pippi F; Arcuri M; Di Cioccio V; Martin LB; Saul A; Micoli F
    J Pharm Biomed Anal; 2017 May; 139():143-147. PubMed ID: 28282600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and validation of an NMR test for the identity and O-acetyl content of the Salmonella typhi Vi capsular polysaccharide vaccine.
    Lemercinier X; Martinez-Cabrera I; Jones C
    Biologicals; 2000 Mar; 28(1):17-24. PubMed ID: 10799051
    [No Abstract]   [Full Text] [Related]  

  • 8. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine.
    Yang HH; Kilgore PE; Yang LH; Park JK; Pan YF; Kim Y; Lee YJ; Xu ZY; Clemens JD
    J Infect Dis; 2001 Jun; 183(12):1775-80. PubMed ID: 11372030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
    Arya SC; Agarwal N
    N Engl J Med; 2009 Nov; 361(22):2191; author reply 2192-3. PubMed ID: 19940305
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of purified Vi polysaccharide typhoid vaccine.
    Park JH; Hong JJ; Choi ES; Lee JW; Park JH
    J Vet Sci; 2002 Jun; 3(2):67-70. PubMed ID: 12441674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
    Pulickal AS; Pollard AJ
    Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
    [No Abstract]   [Full Text] [Related]  

  • 12. Population impact of Vi capsular polysaccharide vaccine.
    Khan MI; Ochiai RL; Clemens JD
    Expert Rev Vaccines; 2010 May; 9(5):485-96. PubMed ID: 20450323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Salmonella typhi Vi conjugate vaccine.
    Koul PA
    N Engl J Med; 2001 Aug; 345(7):545-6. PubMed ID: 11519517
    [No Abstract]   [Full Text] [Related]  

  • 14. Vaccination of active component US military personnel against Salmonella Typhi.
    Porter CK; Sorrell T; Mitra I; Riddle MS
    Vaccine; 2017 Mar; 35(14):1742-1748. PubMed ID: 28268075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salmonella Typhi Vi polysaccharide conjugate vaccine protects infants and children against typhoid fever.
    Crump JA; Oo WT
    Lancet; 2021 Aug; 398(10301):643-644. PubMed ID: 34384541
    [No Abstract]   [Full Text] [Related]  

  • 16. S. Typhi derived vaccines and a proposal for outer membrane vesicles (OMVs) as potential vaccine for typhoid fever.
    Haque S; Swami P; Khan A
    Microb Pathog; 2021 Sep; 158():105082. PubMed ID: 34265371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine--vax-TyVi--in Cuban school children and teenagers.
    Azze RF; Rodríguez JC; Iniesta MG; Marchena XR; Alfonso VM; Padrón FT
    Vaccine; 2003 Jun; 21(21-22):2758-60. PubMed ID: 12798615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH; Kantele JM; Herzog C; Kantele A
    Vaccine; 2014 Jan; 32(5):544-51. PubMed ID: 24342246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
    Schwartz E
    N Engl J Med; 2009 Nov; 361(22):2191-2; author reply 2192-3. PubMed ID: 19950412
    [No Abstract]   [Full Text] [Related]  

  • 20. Vaccines against typhoid fever.
    Guzman CA; Borsutzky S; Griot-Wenk M; Metcalfe IC; Pearman J; Collioud A; Favre D; Dietrich G
    Vaccine; 2006 May; 24(18):3804-11. PubMed ID: 16278037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.